Key result
Beyond blood pressure reduction, ACEIs appear superior to CCBs for prevention of CHD (P=0.028), whereas CCBs appear superior to ACEIs for prevention of stroke (P=0.042).
Why the study?
Do ACEIs and CCBs reduce coronary heart disease and stroke in hypertensive or high-risk patients compared to diuretics, beta-blockers, or placebo?
Meta-Analysis (n=179,122)
Do ACEIs and CCBs reduce coronary heart disease and stroke in hypertensive or high-risk patients compared to diuretics, beta-blockers, or placebo?
While blood pressure lowering is fundamental for cardiovascular prevention, ACEIs provide additional benefits for CHD prevention and CCBs provide additional benefits for stroke prevention beyond blood pressure reduction alone.
Authors
No takes yet. Share an insight, caveat, or question.
Supports tailoring ACEI vs CCB choice to CHD versus stroke risk; confirms differential benefits beyond blood pressure reduction.
Verdecchia et al. (2005) conducted a meta-analysis in Hypertensive or high-risk patients (n=179,122). Angiotensin-converting enzyme inhibitors (ACEIs) and calcium channel blockers (CCBs) vs. Diuretics, beta-blockers, or placebo was evaluated on Coronary heart disease (CHD) and stroke. Beyond blood pressure reduction, ACEIs appear superior to CCBs for prevention of CHD (P=0.028), whereas CCBs appear superior to ACEIs for prevention of stroke (P=0.042).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: